A decrease in surface CD3ε was also noted in cancer patients—both in tumour-infiltrating lymphocytes and peripheral blood T lymphocytes—in-vitro studies suggest that this may possibly be mediated by tumour-derived microvesicles [34]. Here, CD3E is linked to cancer.